ClinConnect ClinConnect Logo
Search / Trial NCT06847750

Elastography Ultrasound in Localized Scleroderma (Morphea) Study

Launched by THE HOSPITAL FOR SICK CHILDREN · Feb 25, 2025

Trial Information

Current as of July 22, 2025

Enrolling by invitation

Keywords

Elastography Ultrasound Scleroderma Quality Of Life Pediatric

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Boys and girls 0-18 years of age at the time of disease onset with a new or existing diagnosis of localized scleroderma (LS) confirmed by a pediatric rheumatologist or dermatologist.
  • Presents with one active or inactive lesion, using the contralateral site for comparison at each visit, as long as the same lesion is evaluated at each time point. OR Presents with more than one lesion as far as both lesions are active or inactive.
  • Able to cooperate with clinical and US evaluation, and the parent or guardian is able to fill out interim patient history form.
  • Exclusion Criteria:
  • Patients with other co-morbidities (e.g. systemic sclerosis, juvenile idiopathic arthritis, other systemic diseases).
  • Patients who present with one active and one inactive lesion.
  • Patients with lesions located in the face or head.

About The Hospital For Sick Children

The Hospital for Sick Children (SickKids) is a leading pediatric health care and research institution located in Toronto, Canada. With a commitment to advancing child health through innovative research, education, and clinical care, SickKids is recognized globally for its expertise in pediatric medicine. The hospital actively sponsors clinical trials aimed at improving treatment outcomes and enhancing the quality of life for children with various health conditions. By fostering collaboration among multidisciplinary teams and leveraging state-of-the-art facilities, SickKids strives to translate research findings into tangible advancements in pediatric care, ensuring that children receive the best possible treatments based on the latest scientific evidence.

Locations

Toronto, Ontario, Canada

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported